<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606329</url>
  </required_header>
  <id_info>
    <org_study_id>HL_LMN_301</org_study_id>
    <nct_id>NCT04606329</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. Versus Charcotrace Inj. in Patients With Nonpalpable Breast Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, Randomized, Open-label, Parallel, Phase 3 Clinical Trial in 8&#xD;
      weeks for screening, once Investigational product injection, Follow up visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of LuminoMark inj. (Conc.&#xD;
      for fluorescence) localization in patients with nonpalpable breast lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Actual">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">January 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Resection margin rate</measure>
    <time_frame>Visit 5 (Day 14 ~Day 24)</time_frame>
    <description>The presence or absence of margin involvement in the resected breast lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>Visit 3 (Day 0)</time_frame>
    <description>The proportion of colored lesion when make an incision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coloring confirmation rate of excision lesion</measure>
    <time_frame>Visit 3 (Day 0)</time_frame>
    <description>The proportion of colored excision lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic perfection</measure>
    <time_frame>Visit 5 (Day 14 ~Day 24)</time_frame>
    <description>Pathologic perfection is how well the surgeon removed the lesion compared to an identified by gross pathologic method. Visit 5, Investigators calculate 'Pathologic perfection' using by the formula. This formula's calculation method is as follows. [Pathologic perfection = the longest diameter of measured lesion by gross(=visual) pathologic method / the longest diameter of removed lesion after surgery]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pigmentation rate</measure>
    <time_frame>Visit 5 (Day 14 ~Day 24)</time_frame>
    <description>Check whether skin is pigmented or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-operation rate</measure>
    <time_frame>Visit 5 (Day 14 ~Day 24)</time_frame>
    <description>The number of subjects who need re-operation is evaluated based on the investigator's comprehensive judgment including histopathology test results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure complication rate</measure>
    <time_frame>Visit 4, 5 (Day 1, Day 14 ~Day 24)</time_frame>
    <description>Evaluate the numbers of subjects with procedure complication after lesion removal</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Breast Diseases</condition>
  <arm_group>
    <arm_group_label>LuminoMark inj.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection LuminoMark inj. 0.2mL once in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Charcotrace Inj.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Charcotrace Inj. about 0.3~1mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LuminoMark inj.(Conc. for fluorescence)</intervention_name>
    <description>Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.</description>
    <arm_group_label>LuminoMark inj.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Charcotrace Inj.</intervention_name>
    <description>Injection Charcotrace Inj. about 0.3~1mL once in this study.</description>
    <arm_group_label>Charcotrace Inj.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 19 years ≤ age ≥ 80 years&#xD;
&#xD;
          2. Those who have lesion vial mammography and breast ultrasound&#xD;
&#xD;
          3. Those who be expected to do operation about non palpable breast lesion excision&#xD;
&#xD;
          4. Written consent voluntarily to participate in this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who be expected to do mastectomy&#xD;
&#xD;
          2. Patients with multiple tumor or diffuse microcalcification&#xD;
&#xD;
          3. Patients who have ink on invasive cancer or ductal carcinoma in situ despite 3 times&#xD;
             local resection&#xD;
&#xD;
          4. Patients who were treated with moderate to severe radiotherapy&#xD;
&#xD;
          5. Patients who were treated with neoadjuvant Chemotherapy&#xD;
&#xD;
          6. Patients with active invading skin connective tissue disease&#xD;
&#xD;
          7. Patients with local progressing breast cancer or inflammatory local progressing breast&#xD;
             cancer&#xD;
&#xD;
          8. Patients who have an allergy to investigational product or any of the component with&#xD;
             the Investigational product&#xD;
&#xD;
          9. Patients who disagree about contraception for this clinical trial&#xD;
&#xD;
         10. A pregnant women or lactating women&#xD;
&#xD;
         11. Patients who participated in other clinical trials within the past 12 weeks from the&#xD;
             date of informed consent&#xD;
&#xD;
         12. Patients who investigators determines unsuitable for this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonpalpable Breast Lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

